Drug Approvals After First-Cycle Review Decline, Parexel Report Finds
This article was originally published in Pharmaceutical Approvals Monthly
FDA's Center for Drug Evaluation & Research cleared fewer NDAs after one review in 2005 than it did the previous year, according to Parexel International's Bio/Pharmaceutical R&D Statistical Sourcebook 2007/2008.
You may also be interested in...
Operation Warp Speed confirmed the necessity of having a facility on hand to develop and manufacture a vaccine for the next crisis, the outgoing advisor says.
Broader use of adaptive trial designs and master protocols, checklist-based application review, and enhancement of real-world monitoring of products are among the recommendations of US FDA's COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) report, an effort months in making based on interviews with agency management, staff, and outside stakeholders.
Shah, deputy commissioner for medical and scientific affairs, has been overseeing FDA’s COVID-19 Pandemic Recovery and Preparedness Plan. His departure the week of 20 January follows that of FDA Chief Counsel Amy Amin, whose resignation led to dueling appointments to temporarily fill her post.